Rosacea Prevalence in General Population - Pilot Study

NCT ID: NCT02292836

Last Updated: 2014-11-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-08-31

Study Completion Date

2013-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test and refine, a subject questionnaire aimed to be used in a general population rosacea prevalence study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will test the subject questionnaire aimed to be used in a full general population prevalence study to screen potential subjects with rosacea.

Questionnaire will be self-administrated to Dermatology outpatients.

Testing will be performed at the practice of 2 Dermatologists experts in rosacea who will evaluate subjects' answers and propose fine-tuning of the questionnaire content, if needed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rosacea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rosacea patients

Questionnaire testing on routine dermatologist patient population

Questionnaire testing

Intervention Type OTHER

Questionnaire testing on rosacea and non-rosacea dermatology outpatients

non-rosacea patients

Questionnaire testing on routine dermatologist patient population

Questionnaire testing

Intervention Type OTHER

Questionnaire testing on rosacea and non-rosacea dermatology outpatients

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire testing

Questionnaire testing on rosacea and non-rosacea dermatology outpatients

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female aged between 18 (or locally accepted majority) and 65 years old both included.
* Subject visiting one of the study dermatology practices for daily care/routine dermatology consultation.
* Subject have to read and sign the approved Informed Consent form prior to any participation in the study,
* Subject willing and capable of cooperating to the extend and degree required by the protocol
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Galderma R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fabien AUDIBERT, Bsc

Role: STUDY_DIRECTOR

Galderma R&D

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jerry TAN

Windsor, Ontario, Canada

Site Status

Mats BERG

Eskilstuna, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD.03.SPR.29105

Identifier Type: -

Identifier Source: org_study_id